Mission Statement, Vision, & Core Values (2026) of Revenio Group Oyj.

Revenio Group Oyj is carving a distinct path in ophthalmic diagnostics with a clear mission to improve clinical diagnostics through targeted product innovations and a vision to be a global leader in comprehensive eye care solutions-backed by a 2024 performance of €103.5 million in net sales and an operating profit of €25.0 million-as it channels roughly 10% of revenues into R&D and commits to stringent quality standards such as ISO 13485; the company's iCare portfolio-from IOP measurement devices to fundus imaging, perimetry and clinical software-supports a strategic 2024-2026 focus on connected, predictive solutions, customer-centric operations, and sustainability initiatives designed to optimize clinical care pathways and deliver measurable value to healthcare professionals and patients alike.

Revenio Group Oyj (0KFH.L) - Intro

• Core product categories: intraocular pressure (IOP) measurement devices, fundus imaging devices, perimeters, and clinical software platforms.
• Market positioning: focused on enabling efficient clinic workflows, point-of-care diagnostics and longitudinal patient monitoring through connected devices and software.
• Customer base: ophthalmologists, optometrists, hospitals, screening programs and research institutions globally.

• Deliver accurate, accessible and minimally invasive ophthalmic diagnostics that enable earlier detection and better management of eye disease.
• Make advanced diagnostic tools simple and scalable for widespread clinical use and screening programs.

• Transform clinical eye care by connecting reliable point-of-care diagnostics with predictive, data-driven clinical pathways that improve outcomes and reduce avoidable vision loss.

• Clinical excellence - evidence-based device performance and validation.
• Customer focus - user-centric design and strong local sales/support to enhance clinical value.
• Innovation - continuous product development emphasizing connectivity and predictive analytics.
• Integrity & responsibility - ethical business conduct and sustainability across operations.

• Product innovation: targeted enhancements to IOP measurement, fundus imaging and perimeter platforms to improve diagnostic accuracy and workflow efficiency.
• Connected solutions: integrated hardware + clinical software to enable predictive diagnostics and streamlined care pathways.
• Customer value: sharpened commercial focus to expand installed base, increase attach rates for software services and improve lifetime customer value.
• Sustainability & operations: reduce environmental footprint across manufacturing and distribution while strengthening responsible governance.

• 2024 sales of €103.5M and operating profit of €25.0M indicate a robust operating margin (~24.2%), underpinning capacity for R&D and geographic expansion.
• Investment focus expected to prioritize connected device ecosystems and clinical software commercialization to capture recurring revenue streams.

Revenio Group Oyj (0KFH.L) - Overview

Revenio's mission is to improve the quality of clinical diagnostics with targeted product innovations. This mission underscores the company's commitment to advancing eye care through continuous innovation and delivering practical diagnostic tools for ophthalmology and primary care.

• Focus: targeted product innovations to enhance clinical diagnostics for eye diseases (glaucoma, retinal conditions).
• Customer-centricity: solutions aimed at clinicians, clinics, and screening programs to improve diagnostic accuracy and patient outcomes.
• Strategic alignment: product development and commercialization priorities directly tied to Revenio's strategic plan for 2024-2026.

Operational priorities derived from the mission:

• Continuous R&D to advance measurement accuracy and usability (portable tonometry, AI-assisted screening tools).
• Global market expansion-strengthening distribution channels in North America, EMEA and APAC.
• Clinical validation and partnerships to accelerate adoption in ophthalmology practices and primary-care settings.

How the mission translates into measurable actions and KPIs:

• Product launches per year: 3-5 targeted innovations (hardware, software, and service enhancements).
• Clinical validation: randomized and real-world studies supporting sensitivity/specificity targets for screening tools.
• Customer satisfaction and retention: reduce churn among high-volume clinic customers; increase recurring service revenues.
• Regulatory and quality metrics: maintain ISO and CE/MDR compliance; expand FDA clearances where strategic.

Strategic investment areas driven by the mission:

• AI and analytics integration to enhance diagnostic interpretation and workflow efficiency.
• Miniaturization and portability of diagnostic devices to enable point-of-care screening.
• Service and consumable ecosystems to create recurring revenue streams tied to device installed base.

Further context on Revenio's long-term orientation and corporate identity is available here: Revenio Group Oyj: History, Ownership, Mission, How It Works & Makes Money

Revenio Group Oyj (0KFH.L) - Mission Statement

• Deliver clinically robust diagnostic instruments and software that improve diagnostic accuracy for glaucoma and other ocular diseases.
• Invest in R&D and partnerships to accelerate innovation and translate research into practical clinical tools.
• Maintain rigorous quality and safety standards (ISO 13485) across product development and manufacturing.
• Expand market access and service capability in Europe and North America while strengthening presence in emerging markets.
• Prioritize customer-centric service models to optimize clinical workflows and long-term client relationships.

• Continuous innovation with targeted R&D investment-approximately 10% of annual revenues devoted to research and product development to sustain technological leadership.
• Broad adoption of integrated diagnostic ecosystems combining imaging hardware, analytics, and cloud-enabled software to support clinicians and telehealth models.
• Focused geographic growth with priority expansion in Europe and North America to capture advanced eye-care markets and reimbursement environments.
• Upholding the highest regulatory and quality benchmarks; all products are developed and maintained in accordance with ISO 13485-certified processes.
• A customer-centric approach designed to improve clinician satisfaction, optimize patient pathways, and encourage long-term institutional partnerships.

• R&D commitment: target ~10% of annual net sales to sustain product pipeline and software development efforts.
• Quality & compliance: ISO 13485-certified QMS to ensure product safety and regulatory readiness for CE marking and FDA pathways where applicable.
• Market focus: prioritized growth in Europe and North America, with distribution networks and clinical partnerships to support adoption.
• Service model: integrated training, remote support, and data services aimed at maximizing uptime and clinician adoption.

• Product pipeline acceleration - bringing next‑generation imaging and analytics to market through sustained R&D funding.
• Regulatory readiness - ensuring timely CE and other regulatory clearances via adherence to ISO 13485 and proactive regulatory affairs planning.
• Clinical evidence generation - expanding peer-reviewed studies and real-world evidence to substantiate clinical and economic value.
• Customer success programs - structured deployment, training, and outcomes tracking to increase satisfaction and device utilization.
• Market expansion - prioritizing sales and support investments in Europe and North America while selectively entering adjacent markets.

Revenio Group Oyj (0KFH.L) - Vision Statement

• Trust and integrity: Revenio prioritizes ethical conduct, regulatory compliance and transparent stakeholder reporting to sustain long-term customer and investor confidence.
• People and teamwork: The company invests in employee development, cross-functional collaboration and a performance culture that treats people as its primary asset.
• Innovation and quality: R&D-led product roadmaps, rigorous quality systems and continuous improvement ensure competitive, high‑accuracy ophthalmic diagnostics.

• Trust & integrity → stringent regulatory pipelines, external audits, and published clinical evidence supporting product claims.
• People & teamwork → cross-border product launches supported by centralized training programs and employee retention metrics tied to incentives.
• Innovation & quality → sustained R&D spending and quality-certification milestones embedded in go-to-market plans.

• Prioritizing product lines with clear clinical evidence and regulatory pathway reduces commercial risk and aligns with trust/integrity.
• Allocation to training and talent retention supports faster international rollouts and preserves institutional knowledge under people/teamwork.
• Steady R&D spend and targeted acquisitions focus on high‑value diagnostic improvements, reflecting innovation/quality priorities.

• Customers: improved diagnostic accuracy and service uptime metrics tied to product SLAs and post‑market surveillance.
• Employees: engagement and retention KPIs inform leadership development and team-based incentives.
• Investors: margin, free cash flow and return on invested capital targets reflect disciplined, values-driven financial stewardship.